<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="60823"><DrugName>oleylphosphocholine (leishmaniasis/Chagas disease/fungal infection), Oblita Therapeutics</DrugName><DrugSynonyms><Name><Value>oleylphosphocholine (leishmaniasis), Max Planck Institute</Value></Name><Name><Value>oleylphosphocholine (leishmaniasis), Dafra Pharma R&amp;D</Value></Name><Name><Value>oleylphosphocholine</Value></Name><Name><Value>D-121 (iv, leishmaniasis/Chagas disease/fungal disease), Dafra Pharma</Value></Name><Name><Value>oleylphosphocholine (leishmaniasis/Chagas disease/fungal infection), Oblita Therapeutics</Value></Name><Name><Value>D-121</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="17962">Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev</CompanyOriginator><CompaniesPrimary><Company id="21182">University of Amsterdam</Company><Company id="1142197">Oblita Therapeutics Bvba</Company><Company id="1068936">European Solutions Enterprise for Neglected Diseases</Company><Company id="1040827">Dafra Pharma R&amp;D</Company></CompaniesPrimary><CompaniesSecondary><Company id="17962">Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev</Company></CompaniesSecondary><CrossReferences><SourceEntity id="60823" type="Drug"><TargetEntity id="435530" type="siDrug">Oleylphosphocholine</TargetEntity></SourceEntity><SourceEntity id="1040827" type="Company"><TargetEntity id="4297884898" type="organizationId">Dafra Pharma NV</TargetEntity></SourceEntity><SourceEntity id="1068936" type="Company"><TargetEntity id="5037362101" type="organizationId">European Solutions Enterprise for Neglected Diseases</TargetEntity></SourceEntity><SourceEntity id="1142197" type="Company"><TargetEntity id="5052964401" type="organizationId">Oblita Therapeutics BVBA</TargetEntity></SourceEntity><SourceEntity id="17962" type="Company"><TargetEntity id="4298428729" type="organizationId">Max Planck Gesellschaft zur Foerderung der Wissenschaften eV</TargetEntity></SourceEntity><SourceEntity id="21182" type="Company"><TargetEntity id="5000694760" type="organizationId">Amsterdam, University of</TargetEntity></SourceEntity><SourceEntity id="1136" type="ciIndication"><TargetEntity id="B55" type="ICD10"/><TargetEntity id="085" type="ICD9"/><TargetEntity id="10024198" type="MEDDRA"/><TargetEntity id="D007896" type="MeSH"/><TargetEntity id="507" type="ORPHANET"/><TargetEntity id="-1278697184" type="omicsDisease"/><TargetEntity id="848" type="siCondition"/></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"/><TargetEntity id="D009181" type="MeSH"/><TargetEntity id="-2109353222" type="omicsDisease"/><TargetEntity id="817" type="siCondition"/></SourceEntity><SourceEntity id="335" type="ciIndication"><TargetEntity id="B57" type="ICD10"/><TargetEntity id="D014355" type="MeSH"/><TargetEntity id="-1708981827" type="omicsDisease"/><TargetEntity id="1599" type="siCondition"/></SourceEntity><SourceEntity id="2638" type="Action"><TargetEntity id="4622" type="Mechanism">Drugs Targeting Plasmodium falciparum Proteins</TargetEntity><TargetEntity id="4959" type="Mechanism">Drugs Targeting Parasite Proteins</TargetEntity></SourceEntity><SourceEntity id="1748" type="Action"><TargetEntity id="1508" type="Mechanism">Homoserine Dehydrogenase (Fungal) Inhibitors</TargetEntity><TargetEntity id="1059" type="Mechanism">Efflux Pump (Fungal) Inhibitors</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C1">Phase 1 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1136">Leishmania infection</Indication><Indication id="124">Fungal infection</Indication><Indication id="335">Trypanosoma cruzi infection</Indication></IndicationsPrimary><ActionsSecondary><Action id="1748">Fungicide</Action><Action id="2638">Antiparasitic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="596">Injectable formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>J2</Code><Name>SYSTEMIC AGENTS FOR FUNGAL INFECTIONS</Name></Ephmra><Ephmra><Code>P</Code><Name>PARASITOLOGY</Name></Ephmra></EphmraCodes><LastModificationDate>2019-06-29T09:21:49.000Z</LastModificationDate><ChangeDateLast>2018-04-10T00:00:00.000Z</ChangeDateLast><AddedDate>2008-07-17T09:55:59.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1142197" linkType="Company"&gt;Oblita Therapeutics&lt;/ulink&gt; is developing oleylphosphocholine (D-121) for the potential ttreatment of cutaneous, mucosal and visceral leishmaniasis, Chagas disease and invasive fungal infections. By February 2018, the company's pipeline listed the drug as in phase I [&lt;ulink linkID="2005161" linkType="Reference"&gt;2005161&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="1040827" linkType="Company"&gt;Dafra Pharma R&amp;amp;D&lt;/ulink&gt; in collaboration with the &lt;ulink linkID="21182" linkType="Company"&gt;University of Amsterdam&lt;/ulink&gt;, under license from the &lt;ulink linkID="17962" linkType="Company"&gt;Max Planck Society&lt;/ulink&gt;, was developing an injectable formulation of oleylphosphocholine (D-121)  for the potential treatment of leishmaniasis [&lt;ulink linkID="925870" linkType="Reference"&gt;925870&lt;/ulink&gt;]. In March 2014, the drug was listed as being in phase II development  [&lt;ulink linkID="1540750" linkType="Reference"&gt;1540750&lt;/ulink&gt;]. However, no development has been reported for Dafra since then. In March 2012, Dafra Pharma was seeking to outlicense rights [&lt;ulink linkID="1274658" linkType="Reference"&gt;1274658&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In October 2013, the FDA granted oleylphosphocholine Orphan designation for the treatment of leishmaniasis [&lt;ulink linkID="1496574" linkType="Reference"&gt;1496574&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In January 2012, the EMA recommended granting oleylphosphocholine Orphan status  for the treatment of leishmaniasis [&lt;ulink linkID="1255531" linkType="Reference"&gt;1255531&lt;/ulink&gt;]; in April 2012, the drug was awarded Orphan Drug designation [&lt;ulink linkID="1293411" linkType="Reference"&gt;1293411&lt;/ulink&gt;]. In August 2016, the orphan drug designation was transferred to Oblita Therapeutics [&lt;ulink linkID="2005159" linkType="Reference"&gt;2005159&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In February 2014, preclinical data were published investigating intradermal delivery of liposomal oleylphosphocholine  using tattooing. In mouse models of Leishmania major and Leishmania mexicana infection, intradermal administration was more effective than topical or intraperitoneal administration in reducing parasite burden [&lt;ulink linkID="2005167" linkType="Reference"&gt;2005167&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; By July 2008, preclinical evaluations had confirmed efficacy; administering the formulation to affected animals led to their full recovery.  Safety and lack of side-effects was also observed in animal studies [&lt;ulink linkID="925870" linkType="Reference"&gt;925870&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In July 2008, Dafra Pharma acquired a license to develop the drug for leishmaniasis from &lt;ulink linkID="1040828" linkType="Company"&gt;Max Planck Innovation&lt;/ulink&gt; (the technology transfer arm of the Max Planck Society) [&lt;ulink linkID="925870" linkType="Reference"&gt;925870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2001, Max Planck published &lt;ulink linkID="PA143375" linkType="Patent"&gt;WO-0172289&lt;/ulink&gt;, claiming liposome-style formulations of phospholipids,  including oleylphosphocholine, for the treatment of tumors and protozoal infections.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1142197">Oblita Therapeutics Bvba</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2018-02-14T00:00:00.000Z</StatusDate><Source id="2005161" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1142197">Oblita Therapeutics Bvba</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2018-02-14T00:00:00.000Z</StatusDate><Source id="2005161" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1142197">Oblita Therapeutics Bvba</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2018-02-14T00:00:00.000Z</StatusDate><Source id="2005161" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="21182">University of Amsterdam</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2012-03-26T00:00:00.000Z</StatusDate><Source id="1274658" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1068936">European Solutions Enterprise for Neglected Diseases</Company><Country id="NL">Netherlands</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2012-03-26T00:00:00.000Z</StatusDate><Source id="1274658" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2013-10-25T00:00:00.000Z</StatusDate><Source id="1496574" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2015-09-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2015-09-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2015-09-12T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17962">Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925870" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2008-07-16T00:00:00.000Z</StatusDate><Source id="925870" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2014-03-12T00:00:00.000Z</StatusDate><Source id="1540750" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="335">Trypanosoma cruzi infection</Indication><StatusDate>2014-03-12T00:00:00.000Z</StatusDate><Source id="1540750" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1040827">Dafra Pharma R&amp;D</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="124">Fungal infection</Indication><StatusDate>2014-03-12T00:00:00.000Z</StatusDate><Source id="1540750" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17962">Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev</Company><Country id="DE">Germany</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1136">Leishmania infection</Indication><StatusDate>2008-07-15T00:00:00.000Z</StatusDate><Source id="925870" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040827">Dafra Pharma R&amp;D</OwnerCompany><Country id="US">US</Country><Indication id="1136">Leishmania infection</Indication><AwardedIndication>Treatment of leishmaniasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-10-25T00:00:00.000Z</MileStoneDate><Source id="1496574" type="CORPORATE"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040827">Dafra Pharma R&amp;D</OwnerCompany><Country id="EU">EU</Country><Indication id="1136">Leishmania infection</Indication><AwardedIndication>Treatment of leishmaniasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2012-04-23T00:00:00.000Z</MileStoneDate><Source id="1293411" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1040827">Dafra Pharma R&amp;D</OwnerCompany><Country id="EU">EU</Country><Indication id="1136">Leishmania infection</Indication><AwardedIndication>Treatment of leishmaniasis</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2012-01-11T00:00:00.000Z</MileStoneDate><Source id="1255531" type="PR"/></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031290">Dafra Pharma International</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="17962">Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCCCCCCC/C=C\CCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C</Smiles></StructureSmiles><Deals><Deal id="114021" title="Dafra to develop Max Planck's oleylphosphocholine"/></Deals><PatentFamilies><PatentFamily id="1565784" number="WO-2012095500" title="Pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration"/><PatentFamily id="1616924" number="WO-00172289" title="Medicament for the stimulation of leucopoiesis and treatment of tumor and protozoan diseases acarinosis and arthropod-borne diseases and a method for production thereof"/><PatentFamily id="2214354" number="WO-2012069427" title="Solid dosage forms of oleylphosphocholine"/><PatentFamily id="969808" number="WO-2012119870" title="Oleyl phosphocholine for the treatment of mycosis"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Dafra Pharma International" id="1031290"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Oblita Therapeutics Bvba" id="1142197"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Max-Planck Gesellschaft Zur Förderung Der Wissenschaften Ev" id="17962"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>